SkyCell AG is a Swiss-based company that operates in the pharmaceutical distribution sector. The company was founded in 2012 by Richard Ettl and Nico Ros, with the aim of revolutionizing the way pharmaceuticals are transported around the world. SkyCell AG has developed a range of innovative solutions that address the challenges of temperature-sensitive pharmaceuticals, ensuring that they are transported safely and effectively.

The pharmaceutical industry is one of the most regulated industries in the world, and the transportation of pharmaceuticals is no exception. The transportation of pharmaceuticals requires strict adherence to temperature control, as any deviation from the required temperature range can compromise the quality and efficacy of the drugs. SkyCell AG has developed a range of solutions that address this challenge, ensuring that pharmaceuticals are transported in a safe and effective manner.

One of the key challenges facing the pharmaceutical industry today is the need to reduce carbon emissions. The transportation of pharmaceuticals is a significant contributor to carbon emissions, and SkyCell AG is committed to decarbonisation. The company has set ambitious targets to reduce its carbon emissions, and is actively working to achieve these targets. SkyCell AG is committed to using renewable energy sources wherever possible, and has implemented a range of initiatives to reduce its carbon footprint.

One of the key initiatives that SkyCell AG has implemented is the use of corporate energy. Corporate energy is a term used to describe the energy that is generated by a company’s own operations. SkyCell AG has implemented a range of measures to reduce its energy consumption, including the use of energy-efficient lighting and heating systems. The company has also invested in renewable energy sources, such as solar panels, to generate its own energy.

Another key initiative that SkyCell AG has implemented is the use of corporate power purchase agreements (PPAs). A corporate PPA is a contract between a company and a renewable energy provider, where the company agrees to purchase a certain amount of renewable energy at a fixed price. SkyCell AG has entered into a number of corporate PPAs, which has enabled the company to source renewable energy at a competitive price.

SkyCell AG is committed to reducing its carbon footprint, and is actively working to achieve this goal. The company has implemented a range of initiatives to reduce its energy consumption and increase its use of renewable energy sources. SkyCell AG is also committed to the use of corporate PPAs, which has enabled the company to source renewable energy at a competitive price.

In addition to its commitment to decarbonisation, SkyCell AG is also committed to innovation. The company has developed a range of innovative solutions that address the challenges of temperature-sensitive pharmaceuticals. SkyCell AG’s solutions are designed to ensure that pharmaceuticals are transported in a safe and effective manner, regardless of the temperature conditions.

One of the key innovations developed by SkyCell AG is its patented temperature-controlled containers. These containers are designed to maintain a constant temperature range, regardless of the external temperature conditions. The containers are equipped with a range of sensors and monitoring systems, which enable SkyCell AG to track the temperature and location of the containers in real-time.

Another key innovation developed by SkyCell AG is its cloud-based software platform. The platform is designed to provide real-time visibility of the transportation process, enabling SkyCell AG to monitor the temperature and location of the containers at all times. The platform also provides customers with access to a range of data and analytics, enabling them to make informed decisions about their supply chain.

SkyCell AG is committed to innovation, and is constantly working to develop new solutions that address the challenges of temperature-sensitive pharmaceuticals. The company’s innovative solutions are designed to ensure that pharmaceuticals are transported in a safe and effective manner, regardless of the temperature conditions.

In conclusion, SkyCell AG is a Swiss-based company that operates in the pharmaceutical distribution sector. The company has developed a range of innovative solutions that address the challenges of temperature-sensitive pharmaceuticals, ensuring that they are transported safely and effectively. SkyCell AG is committed to decarbonisation, and has implemented a range of initiatives to reduce its carbon footprint. The company is also committed to innovation, and is constantly working to develop new solutions that address the challenges of temperature-sensitive pharmaceuticals.